TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29960741

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy in addition to IF electrical stimulation (group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Only biofeedback therapy (group B)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 46
Study: 28985325

Group type: EXPERIMENTAL
Intervention: Telereab-HBP (integrated telerehabilitation home-based programme)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Telereab-HBP
Number of subjects: 112
Study: 27810602

Group type: EXPERIMENTAL
Intervention: Conventional meal plan diet delivered remotely using FaceTime™ on an iPad (RD/CD)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Stop Light diet enhanced with portion-controlled meals (PCMs) delivered remotely using FaceTime™ on an iPad (RD/eSLD)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional diet delivered during face-to-face home visits (FTF/CD)
Number of subjects: 123
Study: 24461582

Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg once daily)
Number of subjects: 16
Study: 22507362

Group type: EXPERIMENTAL
Intervention: Hand exercise intervention (5 exercise sessions and a home exercise component over a 12 week period) with usual care
Number of subjects: 480

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 480
Study: 20185615

Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ice pack
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 36
Study: 17428696

Group type: EXPERIMENTAL
Intervention: Rigid internal fixation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Wire osteosynthesis
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Larger advancements
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Genioplasty
Number of subjects: 127
Study: 15067624

Group type: EXPERIMENTAL
Intervention: Levosulpiride 25 mg, 3 times daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cisapride 10 mg, 3 times daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cisapride
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Levosulpiride
Number of subjects: 140
Study: 12542131

Group type: EXPERIMENTAL
Intervention: Action-task participants (stamped the target with a handheld block)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition-task participants (lifted the block through a target-compatible gap)
Number of subjects: 0
Study: 7667550

Group type: EXPERIMENTAL
Intervention: Radio Frequency (RF) at a SAR of 2.5 W/kg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Warm Water (WW) at 40 degrees C
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Insulated Sack (IS)
Number of subjects: 4
Study: 2669567

Group type: EXPERIMENTAL
Intervention: Immunotherapy with standardized Bermuda grass pollen extract
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1013666

Group type: EXPERIMENTAL
Intervention: Timolol (Blocadren) 15-20 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Moduretic (baseline diuretic therapy)
Number of subjects: 24
Study: 30904880

Group type: EXPERIMENTAL
Intervention: Optimised insole plus usual care
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard insole plus usual care
Number of subjects: 76
Study: 28246136

Group type: EXPERIMENTAL
Intervention: Witnessing IPV
Number of subjects: 3427

Group type: EXPERIMENTAL
Intervention: Witnessing IPV and experiencing violence
Number of subjects: 3427
Study: 25713382

Group type: EXPERIMENTAL
Intervention: Auditory enrichment with audio recordings of maternal sounds (mother's voice and heartbeat)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine exposure to hospital environmental noise
Number of subjects: 40
Study: 23260547

Group type: EXPERIMENTAL
Intervention: Low dose autologous muscle derived cells (1, 2, 4, 8 or 16 × 10(6))
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High dose autologous muscle derived cells (32, 64 or 128 × 10(6))
Number of subjects: 38
Study: 22042887

Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: High-Pressure Balloon (HPB) therapy
Number of subjects: 73
Study: 18436157

Group type: EXPERIMENTAL
Intervention: Citicoline (250 mg intravenously twice a day for 14 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17145529

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin plus 5-fluorouracil (PF) (n = 41)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin plus gemcitabine (PG) (n = 34)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cisplatin replaced by carboplatin in concurrent cycles (n = 18)
Number of subjects: 75
Study: 12365864

Group type: EXPERIMENTAL
Intervention: Carbon-coated MAC (CC-MAC) stent
Number of subjects: 46

Group type: COMPARATOR
Intervention: Uncoated MAC (UC-MAC) stent
Number of subjects: 46
Study: 10492544

Group type: EXPERIMENTAL
Intervention: Aerosol reduction device during air polishing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air polisher without aerosol reduction device
Number of subjects: 30
Study: 7571663

Group type: EXPERIMENTAL
Intervention: Cefotaxime plus metronidazole (single dose)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Cefoxitin (control)
Number of subjects: 1010
Study: 7235354

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, sublingual)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (20 mg, sublingual)
Number of subjects: 10
Study: 31364435

Group type: EXPERIMENTAL
Intervention: Stress condition (n=20)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Stress condition (n=16)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition (n=16)
Number of subjects: 36
Study: 30124230

Group type: EXPERIMENTAL
Intervention: Prenatal vitamin A supplementation
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Caregiver-child stimulation
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Verbal and physical punishment
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Maternal education (completion of primary school)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Maternal height (<155 cm)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Prenatal zinc supplementation
Number of subjects: 198
Study: 28219060

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Low-dose Prednisolone
Number of subjects: 204

Group type: COMPARATOR
Intervention: Basic therapy only (WAT)
Number of subjects: 204
Study: 26692981

Group type: EXPERIMENTAL
Intervention: Hyperlink-embedded journal article
Number of subjects: 44

Group type: COMPARATOR
Intervention: Unmodified journal article
Number of subjects: 44
Study: 24265681

Group type: EXPERIMENTAL
Intervention: In Favor of Myself program
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 259
Study: 21613332

Group type: EXPERIMENTAL
Intervention: Adjustment group treatment (6 sessions of 2 hours each)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Adjustment group treatment
Number of subjects: 151
Study: 18047521

Group type: EXPERIMENTAL
Intervention: adalimumab
Number of subjects: 271

Group type: COMPARATOR
Intervention: methotrexate (MTX)
Number of subjects: 271

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 271
Study: 16644338

Group type: EXPERIMENTAL
Intervention: Verapamil sustained release (SR) strategy
Number of subjects: 8045

Group type: EXPERIMENTAL
Intervention: Verapamil SR strategy
Number of subjects: 8045

Group type: COMPARATOR
Intervention: Atenolol strategy
Number of subjects: 8045

Group type: EXPERIMENTAL
Intervention: Trandolapril in the verapamil SR strategy
Number of subjects: 8045

Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 8045
Study: 14618464

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (group 1A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Gluten-free diet after 4 years (group 1B)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy controls (group 2A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Age- and sex-matched controls (group 2B)
Number of subjects: 48
Study: 11030397

Group type: EXPERIMENTAL
Intervention: Protection of the lingual nerve during lower third molar removal
Number of subjects: 300

Group type: COMPARATOR
Intervention: No protection of the lingual nerve during lower third molar removal
Number of subjects: 300
Study: 9058850

Group type: EXPERIMENTAL
Intervention: Electrophysiologic Study guided therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrocardiographic Monitoring guided therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sotalol therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of previous antiarrhythmic drug therapy
Number of subjects: 0
Study: 8198263

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg intravenously
Number of subjects: 541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study: 3069004

Group type: EXPERIMENTAL
Intervention: Fruit-flavoured mask
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (water-moistened mask)
Number of subjects: 41
Study: 29700127

Group type: EXPERIMENTAL
Intervention: 18F‐alfatide II
Number of subjects: 44

Group type: COMPARATOR
Intervention: 18F‐FDG
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of 18F‐alfatide II and 18F‐FDG
Number of subjects: 44
Study: 26675055

Group type: EXPERIMENTAL
Intervention: Vaginal danazol (200mg BID, 30 days before surgery)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intramuscular diphereline (twice with a 28‐day interval)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Vaginal danazol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intramuscular diphereline
Number of subjects: 160
Study: 25335962

Group type: EXPERIMENTAL
Intervention: Moxa cone moxibustion and routine care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moxa box moxibustion and routine care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine care for stroke recovery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 22972524

Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25-100 µg
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Desmopressin 100-400 µg (tablet)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25-50 µg
Number of subjects: 351
Study: 20804428

Group type: EXPERIMENTAL
Intervention: Prefilled dry powder inhalers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple inhaler devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: No inhalation instruction
Number of subjects: 0
Study: 17687648

Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus gefitinib 250 mg daily from day 5 to 16 (Arm A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus gefitinib 250 mg daily from day 1 to 21 (Arm B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm plus placebo (Arm C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined Arms A + B (gefitinib)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Arm A (intermittent gefitinib)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Arm B (continuous gefitinib)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Arm C (placebo)
Number of subjects: 90
Study: 16861734

Group type: EXPERIMENTAL
Intervention: L-carnitine (20 mg/kg, intravenously three times a week after each haemodialysis session)
Number of subjects: 21
Study: 11882101

Group type: EXPERIMENTAL
Intervention: Proactive public health nursing case management
Number of subjects: 129

Group type: COMPARATOR
Intervention: Self-directed approach (Control)
Number of subjects: 129
Study: 9806512

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with 4 ml of 10% lidocaine solution during intracavitary brachytherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo administered during intracavitary brachytherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with 10% lidocaine solution
Number of subjects: 40
Study: 7564921

Group type: EXPERIMENTAL
Intervention: Fish oil (4.0 g/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Safflower oil (4.0 g/day)
Number of subjects: 18
Study: 2539206

Group type: EXPERIMENTAL
Intervention: Naloxone (0.3 mg/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 414205

Group type: EXPERIMENTAL
Intervention: Prolonged intravenous infusion of trinitrin for 24 hours in 12 cases and during 5 at 7 days in 27 cases
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Prolonged intravenous infusion of trinitrin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 7033781

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 31010033

Group type: EXPERIMENTAL
Intervention: 1000 IU of VitD3
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 3 g of BPH
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of VitD3 and BPH
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29313400

Group type: EXPERIMENTAL
Intervention: GoFAR intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FACELAND intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: CONTROL group
Number of subjects: 30
Study: 27043168

Group type: EXPERIMENTAL
Intervention: Gabapentin 100-300 mg after each HD session for one month
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo thrice weekly after each HD session
Number of subjects: 54
Study: 24474818

Group type: EXPERIMENTAL
Intervention: irinotecan plus cisplatin
Number of subjects: 220

Group type: COMPARATOR
Intervention: etoposide plus cisplatin
Number of subjects: 220
Study: 22662738

Group type: EXPERIMENTAL
Intervention: Web-based version of the Community Reinforcement Approach plus motivational incentives
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 500
Study: 19733905

Group type: EXPERIMENTAL
Intervention: Allergen patches (n = 21)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo patches (n = 16)
Number of subjects: 37
Study: 18161401

Group type: EXPERIMENTAL
Intervention: NGM/EE
Number of subjects: 2894

Group type: COMPARATOR
Intervention: Norethindrone acetate/EE
Number of subjects: 2894
Study: 15326195

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 2948

Group type: EXPERIMENTAL
Intervention: Cisplatin plus a new agent
Number of subjects: 2948

Group type: COMPARATOR
Intervention: Carboplatin plus a new agent
Number of subjects: 2948

Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy
Number of subjects: 2948
Study: 11913295

Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide whitening strips
Number of subjects: 0
Study: 9510218

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (0.1 mg/kg intravenously)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7696003

Group type: EXPERIMENTAL
Intervention: Educational seminar series for hospice staff about AIDS care
Number of subjects: 63

Group type: COMPARATOR
Intervention: Comparison group (not specified intervention)
Number of subjects: 63
Study: 2909150

Group type: EXPERIMENTAL
Intervention: Aminophylline (3 mg/kg over 3 minutes)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (20 ml of saline over 3 minutes)
Number of subjects: 8
Study: 71974

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurbiprofen 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31436378

Group type: EXPERIMENTAL
Intervention: Lactic acid 5% mouth wash 3 times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kenalog in Orabase twice daily
Number of subjects: 40
Study: 30942009

Group type: EXPERIMENTAL
Intervention: Electroacupunture applied at specific acupuncture points (Liangqiu, Xuehai, Yinlingquan, Zusanli, Fenglong, Qiuxu) for 30 minutes once a day from the 1st to 7th day after surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electroacupunture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (conventional patient controlled epidural analgesia and oral celecoxib)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 30650498

Group type: EXPERIMENTAL
Intervention: RPH with the simplified M-M surgery
Number of subjects: 1200

Group type: COMPARATOR
Intervention: PPH with the simplified M-M surgery
Number of subjects: 1200
Study: 25740292

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40 mg day -1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study: 26280611

Group type: EXPERIMENTAL
Intervention: Proximally coated femoral components (Group A)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Fully coated femoral components (Group B)
Number of subjects: 207
Study: 23113678

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 6
Study: 19707065

Group type: EXPERIMENTAL
Intervention: Incremental curriculum delivery (modules received over several weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paying for CE credit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modules read and hours spent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater resource use (time spent, modules read)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (all modules at once)
Number of subjects: 0
Study: 17430239

Group type: EXPERIMENTAL
Intervention: Raising plasma insulin to levels that characterize patients with insulin resistance
Number of subjects: 0
Study: 15029217

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study: 12094124

Group type: EXPERIMENTAL
Intervention: GL+CR trial (glucose plus creatine)
Number of subjects: 5

Group type: COMPARATOR
Intervention: GL trial (glucose)
Number of subjects: 5
Study: 9854223

Group type: EXPERIMENTAL
Intervention: Serum hCG level > 1/150 and morphological ultrasonography between 18 and 20 weeks gestation
Number of subjects: 5163

Group type: COMPARATOR
Intervention: Screening with serum markers alone
Number of subjects: 5163
Study: 7620686

Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednicarbate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Base preparation (vehicle)
Number of subjects: 0
Study: 2134659

Group type: EXPERIMENTAL
Intervention: He‐Ne‐Laser treatment
Number of subjects: 90
Study: 30763

Group type: EXPERIMENTAL
Intervention: Lorazepam (3.1 mg daily, b.i.d.)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 31586376

Group type: EXPERIMENTAL
Intervention: Web-based depression improvement program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 26843101

Group type: EXPERIMENTAL
Intervention: Children with DKA
Number of subjects: 57
Study: 26100101

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking
Number of subjects: 106
Study: 24975522

Group type: EXPERIMENTAL
Intervention: High-oleic peanuts (HOP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Conventional peanuts (CVP)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All groups (CT, CVP, HOP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (CT) and Conventional peanuts (CVP)
Number of subjects: 65
Study: 21320721

Group type: EXPERIMENTAL
Intervention: 1 PGF (25 mg dinoprost) at CIDR removal on Day 5
Number of subjects: 562

Group type: COMPARATOR
Intervention: 2 PGF (two doses of 25 mg dinoprost, first dose at CIDR removal on Day 5, second dose 6 h later)
Number of subjects: 562
Study: 19335072

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy with scaling/root planing and oral hygiene instructions
Number of subjects: 40

Group type: COMPARATOR
Intervention: No periodontal therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: No anti-TNF-alpha therapy
Number of subjects: 40
Study: 17766607

Group type: EXPERIMENTAL
Intervention: Placental drainage of fetal blood
Number of subjects: 86

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 86
Study: 15167607

Group type: EXPERIMENTAL
Intervention: Microemulsion cyclosporine (CSA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 22
Study: 11474638

Group type: EXPERIMENTAL
Intervention: r-hGH therapy for 6-12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active acromegaly patients
Number of subjects: 0
Study: 9701130

Group type: EXPERIMENTAL
Intervention: 2‐component acellular pertussis vaccine
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: 5‐component acellular pertussis vaccine
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Whole‐cell pertussis vaccine
Number of subjects: 669

Group type: COMPARATOR
Intervention: Placebo (diphtheria and tetanus toxoids)
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Children with proven pertussis
Number of subjects: 669
Study: 7958670

Group type: EXPERIMENTAL
Intervention: Gastrin-17 (15, 30, and 60 pmol.kg-1.h-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CCK-8 (15 pmol.kg-1.h-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CCK-8 (higher infusion rates)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CCK-8 plus lox
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CCK-8 together with gastrin-17
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meal-stimulated plasma gastrin concentrations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sham feeding-induced acid secretion during lox infusion
Number of subjects: 8